Mobia Medical, Inc. (MOBI)
Market Closed
15 Oct, 08:00 PM
NASDAQ (NGS) NASDAQ (NGS) Primary $
8. 31
-0.05
-0.5981%
$
282.62M Market Cap
- P/E Ratio
- Div Yield
65,800 Volume
- Eps
$ 8.36
Previous Close 
Want to track MOBI and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Mobia Medical, Inc. (MOBI) Q2 2026 Earnings Call Transcript
Mobia Medical, Inc. (MOBI) Q2 2026 Earnings Call Transcript
Seekingalpha | 2 months ago
Mobia Medical Q2 Earnings Call Highlights
Mobia Medical NASDAQ: MOBI reported second-quarter revenue of $13.5 million, up 102% from $6.7 million a year earlier, as adoption of its Vivistim paired vagus nerve stimulation therapy expanded across new and existing stroke-care programs.
Marketbeat | 2 months ago
Mobia Medical poised for commercial expansion, BofA says in initial coverage
Mobia Medical (NASDAQ:MOBI) was initiated with a ‘Buy' rating and a $16 price target by Bank of America, which cited the company's growth potential in stroke recovery treatment and a large addressable market for its Vivistim system. Mobia's Vivistim therapy combines rehabilitation exercises with a vagus nerve stimulation (VNS) device designed to help chronic stroke survivors improve upper-limb function.
Proactiveinvestors | 4 months ago
2026 © Marketlog. All Rights Reserved.
